/
ENLV
$1.77-$0.15 (-8.15%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$31.0M
17M shares
52-week range
$1.68 – $31.50
0% from low
Exchange
NASDAQ
CS
Change$-170.66
Enlivex Ltd. Ordinary Shares
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
www.enlivex.com- Employees
- 34
- IPO / List date
- Jul 31, 2014
Held by traders on TradeandTell
No one on the platform currently holds ENLV.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 128,192 | $119.2K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-07-09 | 1-for-15reverse |
| 2019-03-06 | 1-for-8reverse |
| 2017-09-25 | 1-for-5reverse |
Recent trades on TradeandTell
No one on the platform has traded ENLV yet.
